摘要
目的:探讨术前超短期应用阿托伐他汀对急性冠脉综合征(ACS)介入治疗后无复流的预防作用。方法:选取ACS行介入治疗患者74例,随机分为两组,各37例。对照组患者常规行介入治疗,观察组患者在术前超短期应用阿托伐他汀口服。对两组患者进行TIMI分级评价,统计无复流发生率;测定两组患者治疗前后血清hsCRP和MCP-1水平。结果:两组行冠脉综合征患者行介入治疗后,观察组5.41%的患者发生无复流,明显少于对照组21.62%的比例,有统计学意义(P<0.05)。两组患者入院时及术后24h血清hsCRP和MCP-1水平相差不大(P>0.05)。术后1周观察组患者hsCRP和MCP-1分别为(2.28±0.91)mg/L和(398.78±82.06)ng/L,明显低于对照组,有统计学意义(P<0.05)。结论:对ACS患者实施介入治疗前超短期应用阿托伐他汀有利于取得介入治疗的最好效果。
Objective：The ultra-short-term application of preoperative atorvastatin preventive effect of no-reflow after interventional treatment of acute coronary syndrome（ACS）.Methods：The selected ACS interventional treatment patients,74 patients were randomly divided into two groups,37 cases each.Routine interventional treatment of patients with the control group,the observation group were the ultra-shortterm application of preoperative atorvastatin orally.Of the two groups of patients with TIMI grade evaluation,statistical incidence of noreflow;determination of two groups of patients before and after treatment serum hsCRP and MCP-1 levels.Results：The two groups underwent coronary syndrome interventional treatment,the observation group was 5.41% in patients with no-reflow,significantly less than the control group,the proportion of 21.62%,a statistically significant（P0.05）.Admission and 24h after serum hsCRP and MCP-1 level of the two groups of patients（P0.05） or less.After 1 week observation group patients hsCRP and MCP-1（2.28 ± 0.91） mg / L and（398.78 ± 82.06） ng / L,significantly lower than the control group,a statistically significant（P0.05）.Conclusion：Implementation of interventional treatment before short-term application Atto atorvastatin to facilitate access to the best effect of interventional treatment of ACS patients.
出处
《中国医药导刊》
2012年第10期1756-1757,共2页
Chinese Journal of Medicinal Guide
关键词
阿托伐他汀
急性冠脉综合征
无复流
超短期应用
Atorvastatin
Acute coronary syndrome
No reflow
Ultra-short-term application
